Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-10-05
2010-11-09
Seaman, D. Margaret (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S300000, C546S121000, C544S362000
Reexamination Certificate
active
07829568
ABSTRACT:
Substituted 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-ylamine compounds corresponding to formula I, methods for the preparation thereof, pharmaceutical compositions containing said compounds, the use of said compounds for preparing pharmaceutical compositions and related treatment methods.
REFERENCES:
patent: 5420138 (1995-05-01), Corbier et al.
patent: 2002/0183327 (2002-12-01), Gerlach et al.
patent: 2003/0022914 (2003-01-01), Maul et al.
patent: 2004/0204409 (2004-10-01), Ando et al.
patent: 2007/0004736 (2007-01-01), Kubo et al.
patent: 0 556 080 (1993-08-01), None
patent: WO 01/53298 (2001-07-01), None
patent: WO 01/72748 (2001-10-01), None
patent: WO 02/081475 (2002-10-01), None
patent: WO 2004/024074 (2004-03-01), None
patent: WO 2004/048363 (2004-06-01), None
patent: WO 2004/074290 (2004-09-01), None
patent: WO 2004/089366 (2004-10-01), None
Paetzel et al., Liebigs Annalen der Chemie (1991), (9), pp. 975-978.
International Preliminary Report on Patentability (English Translation) Nine (9) pages.
International Search Report dated Aug. 3, 2006 with English translation of relevant portion and PCT/ISA/237 (Eleven (11) pages).
German Search Report dated Dec. 29, 2005 with English translation of relevant portion (Nine (9) pages).
E. G. Gray, et al., “The Isolation of Nerve Endings from Brain; An Electron-Microscopic Study of Cell Fragments Derived by Homogenization and Centrifugation”, Department of Anatomy, University College London, and the Biochemistry Department, Agricultural Research Council Institute of Animal Physiology, Babraham, Cambridge, pp. 79-96, vol. 96, Part 1.
Louis J Ravin, “Preformulation” Pharmaceutics Department, SmithKline Beckman Corporation, pp. 1409-1423, Chapter 76.
Anthony R. Disanto, “Bioavailability and Bioequivalency Testing”, Clinical Biopharmaceutics/New Formulation Development, The Upjohn Company, pp. 1424-1431, Chapter 77.
Adelbert M. Knevel, “Separation”, Purdue University: School of Pharmacy and Pharmacal Sciences, pp. 1432-1442, Chapter 78.
G. Briggs Phillips, “Sterilization” , Health Industries Manufacturers Association, pp. 1443-1454, Chapter 79.
Frederick P. Siegel, “Tonicity, Osmoticity, Osmolality and Osmolarity”, College of Pharmacy, University of Illinois, pp. 1455-1472, Chapter 80.
Robert L. Giles, et al., “Plastic Packaging Materials”, Glenn Beall Engineering, Inc. et al, pp. 1473-1477, Chapter 81.
Carl J. Lintner, “Stability of Pharmaceutical Products”, Lintner Associates, pp. 1478-1486, Chapter 82.
Clyde R. Erskine, Jr., “Quality Assurance and Control”, SmithKline Beckman Corporation, pp. 1487-1491, Chapter 83.
J. G. Nairn, “Solutions, Emulsions, Suspensions and Extractives”, Faculty of Pharmacy, University of Toronto, pp. 1492-1517, Chapter 84.
Kenneth E. Avis, “Parenteral Preparations”, College of Pharmacy, University of Tennessee Center for the Health Sciences, pp. 1518-1541, Chapter 85.
Salvatore J. Turco, et al., “Intravenous Admixtures”, Temple University School of Pharmacy et al., pp. 1542-1552, Chapter 86.
John D. Mullins, “Ophthalmic Preparations”, Alcon Laboratories: Research and Development , pp. 1553-1566, Chapter 87.
Lawrence H. Block, “Medicated Applications”, Duquesne University School of Pharmacy, pp. 1567-1584, Chapter 88.
Edward G. Ripple, “Powders”, University of Minnesota: College of Pharmacy, pp. 1585-1602, Chapter 89.
Robert E. King et al., “Oral Solid Dosage Forms”, Philadelphia College of Pharmacy and Science, pp. 1603-1632, Chapter 90.
Stuart C. Porter, “Coating of Pharmaceutical Dosage Forms”, Colorcon, Inc., pp. 1633-1643, Chapter 91.
Mark A. Longer et al., “Sustained-Release Drug Delivery Systems”, University of Wisconsin: School of Pharmacy, pp. 1644-1661, Chapter 92.
John J. Sclarra et al., “AEROSOLS”, Arnold & Marie Schwartz College of Pharmacy and Health Sciences, pp. 1662-1677, Chapter 93.
M. Sako, “Product Class 18:Pyridopyridazines”, Science of Synthesis: Houben-Weyl, Methods of Molecular Transformations, 2004, pp. 1109-1112, and 1115-1153, Category 2, vol. 16, Georg Theime Verlag, New York.
Akimori Wada et al., “Synthesis of Pyrido [4,3-d] pyrimidin-5(6H)-onesviaAnionic Cycloaddition of Methyl 2,4-Dimethoxy-6-methyl-5-pyrimidinecarboxylate with Imines”, Chem. Pharm. Bull., May 1991, pp. 1189-1192, vol. 39, No. 5, 1991 Pharmaceutical Society of Japan.
Hiroki Takahata et al., “Reaction of Lactim Ethers with 2-Caebethoxymethyl Piperidines”, Abstracts of Papers 12thCongress of Heterocyclic Chemistry, Oct. 22, 1979, pp. 296-300, Tokyo, Japan.
Frank Robert
Sundermann Bernd
Sundermann Corinna
Crowell & Moring LLP
Gruenenthal GmbH
Rahmani Niloofar
Seaman D. Margaret
LandOfFree
Substituted... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4225203